Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #Cancer #FDA Approval #Novo Nordisk #Pfizer

Tag: Masimo

Merger & Acquisitions Business Healthcare & Pharmaceuticals News

Danaher Acquisition of Masimo Completed in $9.9B Diagnostics Mega-Deal

  • By BiotechReality Business Intelligence Desk
  • 11 June 2026
Danaher Business System Updates

Danaher Corporation has finalized its acquisition of Masimo Corporation, establishing the pulse oximetry and patient monitoring provider as a stand-alone operating company within its Diagnostics segment.

Tagged Acquisition, Danaher Corporation, Masimo
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRDMO
  • CRO
  • Cybersecurity
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

Sanofi Ends Amlitelimab Atopic Dermatitis Development, Will Not Seek Global Regulatory Approval
Clinical Trials Healthcare & Pharmaceuticals News

Sanofi Ends Amlitelimab Atopic Dermatitis Development, Will Not Seek Global Regulatory Approval

25 July 202625 July 2026
Clinical Trials & Data Desk
Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion
Business CDMO Healthcare & Pharmaceuticals Manufacturing News

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

24 July 202624 July 2026
Editor's Desk
Danaher Corporation Q2 2026 Financial Results; Strategic Capital Allocation, and Market Valuation Dynamics
Business Healthcare & Pharmaceuticals News

Danaher Corporation Q2 2026 Financial Results; Strategic Capital Allocation, and Market Valuation Dynamics

23 July 202623 July 2026
BiotechReality Business Intelligence Desk
Novartis Q2 2026 Results: Kisqali, Kesimpta, and Pluvicto Drive Return to Sales Growth
Business Healthcare & Pharmaceuticals News

Novartis Q2 2026 Results: Kisqali, Kesimpta, and Pluvicto Drive Return to Sales Growth

22 July 202622 July 2026
BiotechReality Business Intelligence Desk
Novo Nordisk Eli Lilly Lawsuit: Novo Nordisk Sues Eli Lilly Over Misleading Wegovy, Ozempic Ad Comparisons
Legal and Patent Affairs Healthcare & Pharmaceuticals News

Novo Nordisk Eli Lilly Lawsuit: Novo Nordisk Sues Eli Lilly Over Misleading Wegovy, Ozempic Ad Comparisons

21 July 202622 July 2026
Legal and IP Desk
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
Regulatory Approval Healthcare & Pharmaceuticals News

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

18 July 202617 July 2026
Regulatory Intelligence Desk
Advertisement
BiotechReality JobFinder

  • Regulatory Strategist – Sanofi
    25 July 2026
  • Global Campaign Specialist – Pall Corporation
    23 July 2026
  • Key Account Manager Bioprocess – Cytiva
    20 July 2026
  • Quality Specialist – Thermo Fisher Scientific
    17 July 2026
  • HSE Specialist – Novartis
    17 July 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter